De-intensification strategies in HPV-related oropharyngeal squamous cell carcinoma—a narrative review

Abstract

Human papillomavirus-related (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) is a relatively new clinical entity that is dramatically on the rise globally. HPV+ OPSCC is thought to be a separate clinical entity compared to HPV− OPSCC with a distinct tumor biology. Patients with HPV associated disease have been shown to have a substantially better prognosis and overall survival than those patients with the HPV negative (HPV−) counterpart. The standard of care for OPSCC is definitive radiation therapy (RT) and concurrent chemoradiation therapy (CRT), for lower and higher stage disease, respectively. However, traditional CRT is also associated with severe acute and late toxicities affecting patient quality of life, such as severe mucositis, dry mouth and dysphagia. Considering that HPV+ OPSCC is on the rise in a younger, healthier patient population and the good prognosis of HPV-related disease, there has been a focus on reducing treatment toxicities and optimizing quality of life while maintaining favorable oncologic outcomes. A variety of such de-escalation regimens are currently being explored in recently completed and ongoing clinical trials. Alterations to the standard chemotherapy, radiation and surgical regimens are being explored. This review will provide an overview of the rationale for and available results of the major de-intensification strategies in the treatment of locally advanced HPV+ OPSCC.

Introduction

Human papillomavirus-related (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) is a relatively new clinical entity that is dramatically on the rise globally (1). HPV+ OPSCC is thought to be a separate clinical entity compared to HPV− OPSCC with a distinct tumor biology. About 60% of oropharynx cancers are associated with HPV infection. The incidence has been increasing in recent years, especially in individuals under the age of 45. This change is attributed to the increasing prevalence of HPV infection in developed countries, the practice of oral sex, and the rising number of sexual partners. HPV+ OPSCC is mediated by infection with the human papilloma virus, which targets the p53 and pRb tumor suppressor pathways and results in cell cycle alteration.

Patients with both HPV+ and HPV− disease can present with vague symptoms including sore throat, dysphagia, odynophagia or ear pain. However, patients presenting with HPV+ disease are usually younger, healthier and without the usual risk factors of aerodigestive tract malignancy such as significant smoking or alcohol use. Additionally, patients with HPV+ disease are often relatively asymptomatic, presenting instead with a painless neck mass and no other symptoms. Fortunately, patients with HPV+ OPSCC have been shown to have a substantially better prognosis and overall survival than those with the HPV− counterpart, even when presenting with similar disease burden (2). A separate TNM staging system through the American Joint Committee on Cancer (AJCC) 8^th edition has been developed resulting in downstaging of many patients with HPV+ OPSCC. Figure 1 shows a representative positive emission tomography/computer tomography (PET/CT) of a patient with locally advanced base of tongue HPV+ OPSCC. This patient has a left sided base of tongue tumor and bilateral enlarged, hypermetabolic cervical lymph nodes. By the AJCC 8^th edition, this patient would be stage II.

Figure 1.

Positive emission tomography/computer tomography (PET/CT) of a patient with locally advanced base of tongue HPV+ OPSCC. (A) Axial view. (B) Coronal view.

While there are different staging systems for HPV+ and HPV− disease, current treatment strategies are the same for both entities. The standard of care for both subtypes of OPSCC is definitive radiation therapy (RT) and concurrent chemoradiation therapy (CRT), for lower and higher stage disease, respectively. However, traditional RT and CRT are also associated with severe acute and late toxicities affecting patient quality of life, such as severe mucositis, dry mouth and dysphagia.

De-intensification, or the reduction in some element of the cancer treatment regimen, is of great interest in HPV+ OPSCC. Considering that HPV+ OPSCC commonly presents in a younger, healthier patient population compared to HPV-negative and the good prognosis of HPV related disease, there has been a focus on reducing treatment toxicities and optimizing quality of life while maintaining favorable oncologic outcomes. As a result, several de-intensification regimens have been proposed in select patient populations. In the past several years alone, there have been numerous studies and trials investigating de-intensification therapy. The recent completion of clinical trials such as the RTOG-1016 trial, the De-SCALaTE HPV trial, and the ORATOR trial have produced interesting and exciting results.

A variety of such de-escalation regimens are currently being explored in recently completed and ongoing clinical trials (Table 1). This review provides a modern overview of the rationale for and available results of the major de-intensification strategies in the treatment of locally advanced HPV+ OPSCC. Great advances have been made in the past five years, and recent completion of a number of large clinical trials on de-escalation in the. past couple years have improved our understanding of the treatment of this disease. We present the following study in accordance with the Narrative Review reporting checklist (available at http://dx.doi.org/10.21037/atm-20-2984).

Table 1. Active clinical trials for de-escalated treatment strategies (clinicaltrials.gov).

Strategy	Clinical trial number	Target population	Intervention/treatment	Primary outcomes
Cetuximab in place of cisplatin	NCT01663259 (3)	7th edition stage III-IV disease (excluding N3 or T4), smoking history <10 pack years	Cetuximab given in place of cisplatin during concurrent CRT	Recurrence rate at 3 years
Immunotherapy in place of cisplatin	NCT03799445 (4)	8th edition stage 1 and 2 (T1 N2, T2 N1-N2, T3 N0-N2) excluding T1N0-N1 and T2N0	Single arm study of IMRT with nivolumab and ipilimumab in place of cisplatin	Dose limiting toxicity, complete response rate at 6 months, progression free survival at 2 years
Radiation therapy dose reduction and/or omission of adjuvant chemotherapy	NCT03323463 (5)	AJCC 8th edition T1-2/N1-2b	Patients receive reduced dose RT (30 Gy) over 2 weeks during concurrent CRT	Treatment effectiveness at 2 years
	NCT02254278 (NRG HN002 trial) (6)	AJCC 7th edition T1-T2, N1-N2b or T3, N0-N2b	Patients randomized to receive 60 Gy RT with or without weekly cisplatin	Dysphagia severity, 2-year progression free survival
	NCT03952585 (7)	AJCC 8th edition T1-2, N1, M0 or T3, N0-N1, M0	Patients randomized to receive standard CRT, reduced dose RT with cisplatin, or reduced dose RT with nivolumab	2-year progression free survival and quality of life (MDADI)
Induction chemotherapy followed by reduced radiation or chemoradiation	NCT04012502 (8)	AJCC 8th edition T1-2/N1-3 (except T1N1M0 and single LN <3 cm) or T3-4N0-3M0 in China	Patients with good response to induction chemotherapy undergo reduced dose adjuvant RT (60 Gy) and omit concurrent cisplatin	2-year progression free and overall survival
Surgery followed by reduced adjuvant therapy	NCT02215265 (PATHOS Trial) (9)	AJCC TNM 7th edition stage T1-T3, N0-N2b	Transoral laser resection of tumors followed by reduced dose adjuvant RT	Overall survival, MD Anderson Dysphagia Inventory (MDADI) score at 2 years
	NCT02908477 (DART-HPV Trial) (10)	Patients who have undergone transoral resection and have T3/T4 primary disease, ENE, LVI, PNI, or N2b disease or below	Transoral resection followed by standard CRT or reduced dose RT with concurrent chemotherapy	Treatment toxicity, overall survival, quality of life
	NCT01898494 (ECOG 3311 Trial) (11)	AJCC 7th T1-T2 OPSCC and N1-N2b neck disease	Transoral resection of tumor and neck dissection followed by risk-adjusted adjuvant treatment	2-year progression free survival
	NCT03729518 (12)	AJCC 7th pathologic T0-3 and N0-N2b disease with <5 positive lymph nodes	Reduced dose (50 Gy) RT with sparing of primary tumor bed in appropriate patients	2-year locoregional control
	NCT01687413 (ADEPT Trial) (13)	Patients that have undergone transoral resection and neck dissection with negative margins at primary site, ECS in nodal metastasis must be present	Reduced dose adjuvant RT and removal of chemotherapy	5-year disease free survival and locoregional control
	NCT03396718 (DELPHI Trial) (14)	Patients who underwent surgical resection HPV+ OPSCC	Intermediate risk patients will be treated with reduced dose RT to tumor and neck	2-year locoregional recurrence

Replacement of cisplatin-based chemotherapy with cetuximab

Several clinical trials have evaluated the potential of the monoclonal anti-EGFR antibody known as cetuximab in place of cisplatin during CRT. The rationale for cetuximab as a treatment for OPSCC was based on Bonner et al.’s 2006 article which reported improved survival rates after addition of cetuximab to RT compared to RT alone for patients with upper aerodigestive squamous cell carcinoma in the IMBL-9815 trial (15). While this study did not specifically look at OPSCC or HPV status, a subgroup analysis in 2010 showed that the benefit conferred through cetuximab was most evident in OPSCC, in younger patients and in those with a better Karnofsky performance score, which pointed towards effectiveness in HPV+ tumors (16). It was thought that cetuximab is less toxic than cisplatin-based chemotherapy; although no study at the time compared cetuximab directly with cisplatin.

The pre-clinical studies of EGFR inhibition in oropharyngeal carcinoma are largely analyzing the role of EGFR-inhibition in HPV-negative disease rather than HPV-positive disease. Currently, there is no preclinical data showing a radiosensitizing effect of cetuximab when added to radiation for HPV-related oropharyngeal cancer. The rationale for EGFR-inhibition in HPV-related oropharyngeal carcinoma is controversial, as it is thought that HPV-related tumors are less driven by such alterations in cell signaling pathways due to the oncogenic properties of HPV-oncoproteins E6 and E7. When compared to HPV-negative carcinoma, HPV-related OPSCC has been shown to harbor fewer driver mutations or alterations such as EGFR-overexpression (17).

Two phase III clinical trials studying the effectiveness of cetuximab in place of cisplatin during concomitant radiation for patients with HPV+ OPSCC have recently published results reporting inferiority of this approach. In the RTOG-1016 study, Gillison et al. [2019] randomized 849 patients to receive cetuximab or cisplatin during chemoradiation. The cetuximab group had a significantly inferior five-year overall survival compared to the cisplatin group (77.9% versus 84.6%, P=0.0163, HR 1.45). Interestingly, there was no significant difference between the rates of acute moderate to severe toxicity (77.4% versus 81.7%, P=0.1586) and late moderate to severe toxicity (16.5% versus 20.4%, P=0.1904) for the cetuximab and cisplatin groups, respectively. This was surprising given that this trial was based on the idea that cetuximab would provide a reduction in toxicity compared to cisplatin, with comparable survival (18).

In the De-SCALaTE HPV trial, Mehanna et al. [2019] randomized 334 patients with locally advanced HPV+ OPSCC with a less than 10 pack year smoking history to receive a chemoradiation regimen with cisplatin or cetuximab. Similar to the RTOG-1016, treatment arms did not differ in the rate of severe and overall acute or late toxicities. However, two-year overall survival was significantly decreased for cetuximab compared to cisplatin (89.4% versus 97.5%, respectively, with P=0.00012 and HR 5) and two-year recurrence rate was also significantly increased for cetuximab (16.1% for cetuximab versus 6% for cisplatin, P=0.0007, HR 3.4). Two-year overall survival rates were statistically significantly different even among patients with stage I/II disease (19).

A third clinical trial (NCT01663259) evaluating cetuximab in place of cisplatin is enrolling patients and has not yet reported results. The trial began in 2011 and recently completed enrolling patients in September 2019. In this study at the University of Michigan, patients with stage III and IV (excluding N3 and T4) HPV related OPSCC and smoking history <10 pack years will receive induction cetuximab followed by concurrent cetuximab and RT at 70 Gy (3). Further trials examining cisplatin-ineligible patients are more important given this finding, as we know that cetuximab does not impart a survival benefit in this population.

Immune checkpoint inhibitors in place of cisplatin-based chemotherapy

Another avenue has been to evaluate the use of immune checkpoint inhibitors in place of conventional chemotherapy. Patients with HPV-related OPSCC are thought to be ideal candidates for immunotherapy as oncogenesis is driven by blockade of the innate immune system. The programmed cell death pathway has been shown to play a role in persistent HPV infection and resistance to elimination by the immune system during malignant progression of disease. Increased levels of programmed death ligand-1 have been shown in HPV-related OPSCC and have also been significantly associated with survival (20). Immunotherapy with monoclonal antibodies targeting these receptors, including immune checkpoint inhibitors ipilimumab and nivolumab, have become standard of care in recurrent or metastatic head and neck squamous cell carcinoma after platinum-based immunotherapy. Additionally, the side effect profile is different and thought to be reduced compared to standard chemotherapy. Common side effects include diarrhea, skin rash, itchiness, pneumonitis, kidney infections and changes in hormone levels. A phase II clinical study with the National Cancer Institute and University of Texas MD Anderson Cancer Center is ongoing to test the safety, tolerability and efficacy of ipilimumab and nivolumab in combination with radiation (up to 60 Gy) in patients with early stage HPV related OPSCC, including patients with T1N2, T2N1-2 and T3N0-2 disease (4). Again, due to the inferiority of cetuximab, the potential use of checkpoint inhibitors is appealing to maximize survival and minimize side effects. Immune modulation represents an exciting new line of therapy that will be further investigated for years to come.

RT dose reduction and/or omission of adjuvant chemotherapy

There is a well-established correlation between cumulative RT dose delivered and short and long-term morbidity. Traditional side effects of RT to the head and neck include dry mouth, mouth sores, jaw stiffness, skin changes, lymphedema, tooth decay, and dysphagia from treatment effects on the muscles of mastication and swallowing. Radiation doses below 60 Gy are associated with improved functional swallowing outcomes (21), whereas each 10 Gy delivered above 55 Gy results in increasing rates of dysphagia (22). HPV related tumors are believed to be more sensitive to RT than HPV− tumors. In vitro and in vivo studies have demonstrated an intrinsic radio-sensitivity of HPV related head and neck cancers (23-25). The mechanism of this is not well understood. HPV-positive cancers may have a higher cellular radio-sensitivity than their HPV− counterparts due to cell cycle dysregulation and impaired DNA repair (26). Therefore, patients with HPV related disease may benefit from lower doses of RT while maintaining the same oncologic result. A number of trials have been conducted along this line of investigation.

In a prospective, multi-institutional phase II study published in 2015, Chera et al. reported on 43 patients treated with reduced dose radiation (60 Gy) along with weekly low-dose cisplatin. Patients were included if they had T0 to T3 and/or N0 to N2c HPV related disease and had a minimal smoking history. Following completion of treatment, patients were evaluated for complete clinical response based on physical and radiologic examination, and pathological clinical response based on planned surgical intervention. Patients underwent directed biopsies at the primary site and those with nodal disease underwent post-treatment neck dissection. The complete pathological response rate was 86%, with decreased incidence of severe and very severe treatment toxicities (27). Long-term follow up from the study was published in 2018. The 3-year local control, regional control, cause-specific survival, distant metastasis-free survival, and overall survival rates were 100%, 100%, 100%, 100%, and 95%, respectively, with favorable quality of life outcomes (28).

A phase two clinical trial (NCT03323463) evaluating reduced dose RT is ongoing at Memorial Sloan Kettering Cancer Center. This is a prospective non-inferiority trial of major radiation dose de-escalation in patients with HPV+ T1-2/N1-2b OPSCC undergoing concurrent chemoradiation. Trial participants will receive 30 Gy radiation over three weeks with two cycles of standard chemotherapy, and will be compared to patients received a standard CRT regimen. Primary endpoint will be effectiveness of treatment at 2 years (5).

An ongoing trial (NCT03952585) combines both reduction in RT dosing and replacement of cisplatin with immune-checkpoint inhibitors. A randomized phase II/III trial is currently underway examining whether a reduced dose of RT and nivolumab works as well as standard dose RT and cisplatin in treating patients with HPV+ oropharyngeal cancer. Patients with AJCC 8^th edition T1-2, N1, M0 or T3, N0-N1, M0 disease are randomized to receive standard CRT, reduced dose RT with cisplatin, or reduced dose RT with nivolumab in place of cisplatin. Primary outcome measures will be progression-free survival at 2 years and quality of life measures (7).

Another line of investigation is to omit systemic therapy altogether for patients with locally advanced disease and treat patients with clinical low-risk disease with radiation alone. The NRG HN002 trial (NCT02254278) is ongoing and is randomizing non-smoking patients with p16-positive locally advanced OPSCC to receive 60 Gy RT with or without weekly cisplatin. The trial recently completed recruiting patients. The primary endpoint will be two-year progression free survival (7).

Given that patients with HPV-related OPSCC are, on average, younger and healthier than their HPV-negative counterparts, and that the side effects of radiation are long lasting, the focus on reduction of radiation volume and omission of toxic adjuvant therapy is appealing to maximize quality of life. These patients likely will have a long life-expectancy after surviving from their cancer. Therefore, this is an exciting line of de-escalation that has the likelihood to make a big impact on patient quality of life as HPV-related OPSCC cancer patients become long term survivors.

Induction chemotherapy followed by reduced radiation or chemoradiation

Various trials have examined induction cisplatin-based chemotherapy followed by reduced radiation doses or volumes. Induction chemotherapy can be used for risk stratification with the assumption that adjuvant RT can be reduced in good responders.

In 2017, Marur et al. published the results of the ECOG 1308 trial which randomized 80 patients with stage III and IV (AJCC 7^th edition) disease to receive an induction regimen followed by either low (54 Gy) or standard dose IMRT with cetuximab, depending on the response to induction chemotherapy (29). Two-year progression free survival and overall survival were 80% and 94%, respectively, for patients with T3 and/or N2b or below disease and those with a smoking history less than 10 years. At one year, significantly fewer patients who were treated with the reduced radiation dose reported difficulty swallowing (40% versus 89%, P=0.011) or impaired nutrition (10% versus 44%, P=0.025).

In a single arm phase II clinical trial, Chen at al. reported on 44 patients with stage III and IV HPV related disease (AJCC 7^th edition) who were randomized to receive low (54 Gy in 27 fractions) or standard dose (60 Gy in 30 fractions) IMRT with paclitaxel, depending on response to an induction chemotherapy regimen (30). Progression free survival was 92% (95% CI, 77–92).

The OPTIMA trial was a phase II radiation dose and volume de-escalation trial of 62 patients with HPV related OPSCC. After a trial of induction chemotherapy, low risk patients (those with ≤T3, ≤N2B, and ≤10 pack-year history) with ≥50% response received 50 Gy RT (RT50), while low risk patients with 30%-50% response or high-risk patients with ≥50% response received 45 Gy CRT (CRT45). Those with lesser responses received a standard chemoradiation regimen (CRT75). Two-year progression free survival and overall survival were 95% and 100% for low-risk patients and 94% and 97% for high-risk patients, respectively. Grade 3+ mucositis occurred in 30%, 63%, and 91% of the RT50, CRT45, and CRT75 groups, respectively (P=0.004), while G-tube rates were 0%, 31%, and 82% for RT50, CRT45, and CRT75 groups, respectively (P<0.0001) (31).

For standard treatment, induction remains highly selective for patients with bulky disease or to try to reduce the radiation field and therefore reduce radiation-associated morbidity. Induction chemotherapy also has to be given with caution so patients do not get too sick from their initial treatment and therefore are unable to continue on to their next step of therapy.

Surgical approaches with de-escalated adjuvant therapy

Traditional open surgical approaches to the oropharynx are associated with substantial morbidity as a result of poor access to the tumors. Advances in minimally invasive surgical therapy including transoral robotic surgery (TORS) and transoral laser microsurgery (TLM) have allowed for improved quality of life and functional outcomes with comparable oncologic results (32-35). For tumors amenable to minimally invasive surgical approaches, the goal is to spare or diminish the need for adjuvant treatment. Several prospective randomized surgical trials with de-escalated adjuvant therapy are underway.

MC1273 was a single-arm phase II trial evaluating reduced-dose of adjuvant RT following transoral surgical resection. Patients with HPV+ OPSCC with a less than 10-pack year smoking history who underwent surgical resection with negative margins were included in the study. Intermediate risk patients received 30 Gy of adjuvant RT over 2 weeks, while patients with extranodal extension on final pathology received 36 Gy. The 2-year locoregional tumor control rate was 96.2%, with progression-free survival of 91.1% and overall survival of 98.7%. Rates of grade 3 or worse toxicity at pre-RT and 1- and 2-year post-RT were 2.5%, 0%, and 0%. Swallowing function improved slightly between pre-RT and 12 months post-RT (36).

ECOG 3311 (NCT01898494) is a phase II clinical trial enrolling patients to investigate reduced doses of adjuvant RT following transoral resection of intermediate-risk HPV+ tumors. Patients with unilateral, low stage (T1-T2) OPSCC and N1-N2b neck disease undergo transoral resection and neck dissection, followed by risk-based adjuvant treatment. Intermediate risk patients, defined as those with N2 or above disease with extra-nodal extension (ENE) ≤1 mm are randomized to receive reduced dose (50 Gy) RT or standard dose (60 Gy). Low stage patients receive no adjuvant treatment. Patients with evidence of ENE pre-operatively or with primary tumors that are likely to result in positive margins during transoral resection are excluded from the study (11).

The Post-Operative Adjuvant Treatment of HPV-Positive Tumors (PATHOS) (NCT02215265) is another phase II trial examining the impact of transoral laser resection of tumors followed by reduced dose adjuvant RT on functional outcomes and survival. Patients undergo TLM resection of tumors, and are then randomized to reduced dose RT or standard dose RT (9).

The Adjuvant De-escalation, Extracapsular Spread, p16 Positive, Transoral (ADEPT) trial (NCT01687413) is a third phase II trial investigating reduced dose adjuvant RT and removal of chemotherapy from the adjuvant regimen of patients with extracapsular spread (ECS) on final pathology. All patients undergo transoral surgical resection and neck dissection. Patients are included in the trial if they have negative margins at the surgical site and must have ECS in nodal metastases on final pathology. Radiation volume is also not delivered to the primary bed in patients with completely resected T1 or T2 disease (13).

The DART-HPV (De-Escalated Adjuvant Radiation Therapy for HPV Associated Oropharynx Cancer) study (NCT02908477) is currently enrolling patients at the Mayo Clinic randomizing patients with HPV+ OPSCC who have undergone transoral resection and meet criteria for adjuvant treatment to receive standard adjuvant CRT or docetaxel with reduced adjuvant RT (30 Gy delivered over two weeks). The primary endpoint is treatment toxicity (10).

A single institution study at the University of Pennsylvania (NCT02159703) evaluated omission of adjuvant RT to the primary site following TORS and selective neck dissection for advanced stage HPV+ disease. This trial enrolled patients with pathologic T1 or T2 stage disease resected with TORS with negative margins and pathologic nodal stage N2a, N2b or N2c. Patients received adjuvant RT to the neck alone, while the primary site was spared. Two-year locoregional control and toxicity rates will be examined. Results have not yet been reported (37).

Finally, the ORATOR trial, an open label, phase II trial in which patients with OPSCC were randomized to receive radiotherapy or TORS with neck dissection recently published results. In this study, 68 adult patients with T1-T2, N0-2 (≤4 cm) OPSCC were randomized to one of the two groups. The primary endpoint was swallowing-related quality of life at one year as established using the MD Anderson Dysphagia Inventory (MDADI) score. They found that patients who underwent radiotherapy had a statistically significant improvement in swallowing one year after completing treatment compared to the surgery group (MDADI score 86.9 versus 80.1, P=0.046) (38). This suggests that radiotherapy may offer improved swallowing outcomes compared to surgery; however, further studies are needed to better understand if this is a clinically significant finding. The conclusion of this trial was particularly surprising given that previous studies suggested that surgery was more favorable compared to radiation in terms of swallowing outcomes. These studies were largely retrospective studies without formal toxicity evaluations. However, critics of the ORATOR trial note that the MDADI is only a subjective measurement of swallowing function and that more objective measures such as a videofluoroscopic swallow study should be used to evaluate swallowing function. As such, patients should be informed of both surgery and chemoradiation as options for their disease, and the benefits and risks of each should be weighed carefully by each patient and provider (39).

As these trials show, the role of surgery in treating HPV-related OPSCC is constantly evolving. Traditional surgical paradigms are being challenged by the behavior of HPV-related cancers. Further studies need to examine the impact of various pathologic factors in surgical outcomes including positive margins and extranodal extension. Because of the strong influence of HPV on biologic behavior and outcome, treatment algorithms must change and evolve, which is evidenced by the numerous clinical trials in this space.

Conclusions

Patients with HPV+ OPSCC fortunately have a good prognosis. Given the severe toxicities associated with standard, traditional treatment approaches to oropharyngeal cancer, there is benefit to investigating de-escalated therapies without compromising survival. Early results of trials comparing cetuximab to cisplatin showing no survival benefit published this year may temper enthusiasm for de-escalation. However, results from trials of reduced doses of RT during concurrent CRT and induction chemotherapy followed by reduced RT based on induction response have demonstrated excellent oncologic and quality of life outcomes. Advances in minimally invasive surgery followed by reduced adjuvant regimens present exciting lines of investigation in ongoing clinical trials, which utilize advances in surgical technique to optimize quality of life and survival. As there is currently a lack of consistent randomized phase III clinical trial results, treatment de-intensification is not recommended outside of ongoing clinical trials. It is important that de-intensification strategies are studied rigorously in order to best define clinical parameters to guide treatment choices. Any decrease in survival should not be tolerated; however, quality of life for patients with HPV+ OPSCC should also be emphasized. Further studies should also evaluate how patients are diagnosed with HPV-related oropharyngeal cancer, and if p16-staining is enough to stratify risk and prognosis. We will eagerly await the results of the numerous ongoing clinical trials in order to best help this patient population.

Supplementary

The article’s supplementary files as

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.